Cotadutide vs Pemvidutide
Head-to-head comparison of Cotadutide (MEDI0382, long-acting GLP-1 and glucagon receptor dual agonist) and Pemvidutide (Pemvidutide (ALT-801), long-acting glucagon-like peptide-1/glucagon receptor dual agonist) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | Cotadutide | Pemvidutide |
|---|---|---|
| Category | Weight Management | Weight Management |
| Full Name | MEDI0382, long-acting GLP-1 and glucagon receptor dual agonist | Pemvidutide (ALT-801), long-acting glucagon-like peptide-1/glucagon receptor dual agonist |
| Molecular Weight | ~4,700 Da | N/A |
| Half-Life | Approximately 24 hours | Approximately 1 week |
| Amino Acids | 37 | N/A |
| Typical Dose | 0.3-3 mg daily in clinical studies | Trial-dependent; once-weekly SC titration |
| Route | Subcutaneous | Subcutaneous |
| Purity | ≥98% | ≥98% |
| Studies Count | 18 | 18 |
| Research Status | Clinical | Clinical |
Cotadutide Benefits
- ✓body-weight reduction
- ✓improved insulin sensitivity
- ✓reduced hepatic fat
- ✓appetite suppression
Pemvidutide Benefits
- ✓appetite suppression
- ✓body-weight reduction
- ✓improved liver-fat markers
- ✓better glycemic control
Cotadutide Dosing
Once-daily SC in trials|Start low and titrate based on tolerance|Monitor GI adverse effects
Pemvidutide Dosing
once-weekly subcutaneous injection|gradual dose escalation|maintenance at tolerated trial dose
Cotadutide Side Effects
- ⚠nausea
- ⚠vomiting
- ⚠diarrhea
Pemvidutide Side Effects
- ⚠nausea
- ⚠vomiting
- ⚠diarrhea
Research Overview
Cotadutide
Phase 2 studies reported dose-dependent weight loss and favorable changes in glycemic and liver-related markers. It is one of the most cited synthetic dual-agonist peptides for obesity research.
Pemvidutide
Clinical studies have reported dose-dependent weight loss and favorable effects on liver fat and transaminases. It remains investigational and is not approved for obesity treatment.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.